| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/03/2001 | CN1278727A A combination of a monomine oxidase inhibitor and a hs-ht antagonist or partial agonist |
| 01/02/2001 | US6169105 Potentiating the action of paroxetine in increasing the availability of serotonin, norepinephrine and dopamine in the brain by administering paroxetine to a patient in need thereof in combination with way 100635 |
| 01/02/2001 | US6169100 Pharmaceutical composition |
| 01/02/2001 | US6169099 Pharmaceutical composition |
| 01/02/2001 | US6169098 Composition and methods employing it for the treatment of 5-HT-mediated disorders |
| 01/02/2001 | US6169069 Therapeutic/cosmetic compositions comprising CGRP antagonists for treating the eyes or eyelids |
| 01/02/2001 | US6168933 Nucleotide sequences coding a transport protein; for the classification, diagnosis, prevention, and treatment of defects in cell proliferation, lipid metabolism and transport |
| 01/02/2001 | US6168920 Extracellular adhesive proteins |
| 01/02/2001 | US6168802 In the last few years there has been considerable interest among athletes in creatine, which occurs abundantly in skeletal muscle. |
| 01/02/2001 | US6168792 Materials and methods for detection and treatment of immune system dysfunctions |
| 01/02/2001 | US6168790 Use of antibodies to block the effects of gram-positive bacteria and mycobacteria |
| 01/02/2001 | CA2001572C Compositions for treating tobacco withdrawal symptoms |
| 01/01/2001 | WO2001003645A2 Methods and apparatus for relieving headaches, rhinitis and other common ailments |
| 12/30/2000 | CA2313131A1 Compositions and treatment for diabetic complications |
| 12/30/2000 | CA2313105A1 Treatment for diabetic complications |
| 12/30/2000 | CA2313063A1 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
| 12/30/2000 | CA2312989A1 Combination therapy for the treatment of migraine |
| 12/30/2000 | CA2312633A1 Combination therapy for the treatment of migraine |
| 12/30/2000 | CA2312631A1 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine |
| 12/28/2000 | WO2000079003A1 Polymorphisms in the human hmg-coa reductase gene |
| 12/28/2000 | WO2000078972A2 Regulation with binding cassette transporter protein abc1 |
| 12/28/2000 | WO2000078971A2 Atp binding cassette transporter protein abc1 popypeptides |
| 12/28/2000 | WO2000078954A2 Human transcriptional regulator proteins |
| 12/28/2000 | WO2000078953A2 Human transport proteins |
| 12/28/2000 | WO2000078952A2 Human rna metabolism proteins (rmep) |
| 12/28/2000 | WO2000078941A2 Methods and products for manipulating uncoupling protein expression |
| 12/28/2000 | WO2000078940A1 In vivo insect model system for type-2 diabetes |
| 12/28/2000 | WO2000078933A2 Novel calpains and their use |
| 12/28/2000 | WO2000078930A1 Method for enhancing hematopoiesis |
| 12/28/2000 | WO2000078805A1 Peptide having preptin functionality |
| 12/28/2000 | WO2000078803A2 Use of eif4e binding agents in therapy |
| 12/28/2000 | WO2000078746A1 Antiviral agents |
| 12/28/2000 | WO2000078355A2 Biologically active materials |
| 12/28/2000 | WO2000078352A1 Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method |
| 12/28/2000 | WO2000078347A1 Cell growth inhibition |
| 12/28/2000 | WO2000078346A1 Novel anti-allergic agents |
| 12/28/2000 | WO2000078330A2 Adenosine diphosphatase and activators thereof and their medical uses |
| 12/28/2000 | WO2000078328A2 USE OF GROWTH HORMONE (hGH) FOR THE TREATMENT OF SEXUAL FUNCTIONAL DISTURBANCES |
| 12/28/2000 | WO2000078322A2 Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions |
| 12/28/2000 | WO2000078320A1 Cartilage enhancing food supplements and methods of preparing the same |
| 12/28/2000 | WO2000078317A1 Integrin receptor antagonists |
| 12/28/2000 | WO2000078304A1 V.n. vassiliev's pharmaceutical composition for restoring the sympatho-adrenal system and method for estimating the efficiency thereof |
| 12/28/2000 | WO2000078303A1 Non-malignant disease treatment with ras antagonists |
| 12/28/2000 | WO2000078299A2 Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy |
| 12/28/2000 | WO2000078268A2 Potentiation of chloroquine |
| 12/28/2000 | WO2000078247A1 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| 12/28/2000 | WO2000061551A3 Pyrimidine-2-one derivatives as integrin receptor ligands |
| 12/28/2000 | WO2000058460A3 Casb619 involved in colon cancers |
| 12/28/2000 | WO2000056301A3 Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| 12/28/2000 | WO2000048625A3 Inhibitors for use in hemostasis and immune function |
| 12/28/2000 | WO2000045851A3 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin |
| 12/28/2000 | WO2000045845A3 Liposome composition and method for administration of a radiosensitizer |
| 12/28/2000 | WO2000044379B1 Methods for restoring and/or enhancing accommodation in pseudo phakia |
| 12/28/2000 | WO2000043495A3 33 human secreted proteins |
| 12/28/2000 | WO2000041526A3 Use of s-triazines for treating apicomplexan parasitic infections |
| 12/28/2000 | WO2000037640A3 Compositions and methods for the treatment of tumor |
| 12/28/2000 | WO2000034474A3 Growth factor homolog zvegf3 |
| 12/28/2000 | WO2000032776A3 Secreted amd transmembrane polypeptides and nucleic acids encoding the same |
| 12/28/2000 | WO2000017369B1 Alzheimer's disease secretase |
| 12/28/2000 | DE19929065A1 Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and HMG-CoA reductase inhibitor |
| 12/28/2000 | DE19929031A1 Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and lipid metabolism regulator or vitamin |
| 12/28/2000 | DE19929012A1 Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and metabolically active drug |
| 12/28/2000 | CA2377524A1 Novel anti-allergic agents |
| 12/28/2000 | CA2377339A1 Administration of growth hormone (hgh) for the therapy of sexual functional disorders |
| 12/28/2000 | CA2376077A1 Integrin receptor antagonists |
| 12/28/2000 | CA2375781A1 Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abci |
| 12/28/2000 | CA2375527A1 Method for enhancing hematopoiesis |
| 12/28/2000 | CA2375508A1 Methods and products for manipulating uncoupling protein expression |
| 12/28/2000 | CA2375493A1 Human transport proteins |
| 12/28/2000 | CA2375484A1 In vivo insect model system for type-2 diabetes |
| 12/28/2000 | CA2375477A1 Novel calpains and their use |
| 12/28/2000 | CA2375414A1 Human transcriptional regulator proteins |
| 12/28/2000 | CA2375407A1 Rna metabolism proteins |
| 12/28/2000 | CA2375211A1 Antiviral agents |
| 12/28/2000 | CA2375207A1 Peptide having preptin functionality |
| 12/28/2000 | CA2374548A1 Biologically active materials |
| 12/28/2000 | CA2373375A1 Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions |
| 12/28/2000 | CA2371924A1 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| 12/28/2000 | CA2368099A1 Adenosine diphosphatase and activators thereof and their medical uses |
| 12/27/2000 | EP1063298A2 Transgenic Animal Model for Alzheimer Disease |
| 12/27/2000 | EP1063292A2 DNA encoding human alpha 1 adrenergic receptors and uses thereof |
| 12/27/2000 | EP1063291A2 DNA encoding human alpha 1 adrenergic receptors and uses thereof |
| 12/27/2000 | EP1062950A2 1,3 Oxathiolane nucleoside analogues |
| 12/27/2000 | EP1062947A1 Remedies for aids |
| 12/27/2000 | EP1062879A1 Aqueous solution for the parenteral nutrition |
| 12/27/2000 | EP1062363A1 Method for producing agents for treating tumour diseases and for immunosuppression |
| 12/27/2000 | EP1062334A1 Mammalian sodium channel proteins |
| 12/27/2000 | EP1062332A2 Human receptor proteins; related reagents and methods |
| 12/27/2000 | EP1062326A1 Glycosyl sulfotransferase-3 |
| 12/27/2000 | EP1062232A2 Molecules that home to various selected organs or tissues |
| 12/27/2000 | EP1062225A1 REPLICATIVE HELICASE dnaB OF $i(STAPHYLOCOCCUS AUREUS) |
| 12/27/2000 | EP1061963A1 Protease inhibitors in absorbent articles |
| 12/27/2000 | EP1061962A1 Disposable absorbent article having a skin care composition containing an enzyme inhibitor |
| 12/27/2000 | EP1061953A1 Analgesic combination comprising nmda receptor antagonists and narcotic analgesics |
| 12/27/2000 | EP1061952A2 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor |
| 12/27/2000 | EP1061925A1 Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist |
| 12/27/2000 | EP1061923A2 Metal chelators for use in the treatment of alzheimer's disease |
| 12/27/2000 | EP1061922A1 USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS |
| 12/27/2000 | EP1061917A1 Methods of inhibiting bone resorption |
| 12/27/2000 | EP1061913A2 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation |